Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.67 |
| ▸ | ACHE | P22303 | 1/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.56 |
| ▸ | TYR | P14679 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19386144 | 0.91 | SNCA (0.62) | SNCAACHEPTGS1TYR | |
| SCHEMBL20873819 | 0.91 | SNCA (0.62) | SNCAACHEPTGS1TYR | |
| SCHEMBL2910488 | 0.89 | ACHE (0.68) | SNCAACHEPTGS1CA12CA1 | |
| Androsin SCHEMBL19590975 | 0.89 | ACHE (0.68) | SNCAACHEPTGS1CA12CA1 | |
| Androsin SCHEMBL8977521 | 0.89 | ACHE (0.68) | SNCAACHEPTGS1CA12CA1 | |
| Androsin SCHEMBL8977529 | 0.89 | ACHE (0.68) | SNCAACHEPTGS1CA12CA1 | |
| Androsin SCHEMBL8977518 | 0.89 | ACHE (0.68) | SNCAACHEPTGS1CA12CA1 | |
| SCHEMBL19798068 | 0.89 | ACHE (0.68) | SNCAACHEPTGS1CA12CA1 | |
| Androsin SCHEMBL8977517 | 0.89 | ACHE (0.68) | SNCAACHEPTGS1CA12CA1 | |
| Androsin SCHEMBL29655138 | 0.89 | ACHE (0.68) | SNCAACHEPTGS1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10966447-B2 | Glucosyringic acid analogs as sweetness profile modifiers | PEPSICO, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| WO-2018017574-A1 | GLUCOSYRINGIC ACID ANALOGS AS SWEETNESS PROFILE MODIFIERS | PEPSICO, INC. (US) | 2018-01-25 | — | — | WO | disclosed |
| US-20180020708-A1 | GLUCOSYRINGIC ACID ANALOGS AS SWEETNESS PROFILE MODIFIERS | PEPSICO, INC. | 2018-01-25 | — | — | US | disclosed |
| US-20180020708-A1 | GLUCOSYRINGIC ACID ANALOGS AS SWEETNESS PROFILE MODIFIERS | PEPSICO, INC. | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10966447-B2 | Glucosyringic acid analogs as sweetness profile modifiers | GPR119, TAS2R42, TAS2R31 | SNCA 2191/4885ACHE 3935/4885PTGS1 1985/4885 |
| US-20180020708-A1 | GLUCOSYRINGIC ACID ANALOGS AS SWEETNESS PROFILE MODIFIERS | GPR119, TAS2R42, TAS2R31 | SNCA 2191/4885ACHE 3935/4885PTGS1 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.